Sage Journals: Discover world-class research

Abstract

Background

The development of angioedema is a rare yet serious clinical event that may develop due to an adverse drug reaction. Rapid recognition and treatment of this adverse reaction is critical for optimal patient outcomes; however, prevention of this occurrence is preferred.

Case report

A 59-year-old woman presented to the emergency department with lingual angioedema caused by the addition of everolimus to her medication regimen. The patient improved after withdrawal of the offending agent and standard treatment. Early recognition by healthcare providers and management of everolimus-induced angioedema is vital for successful patient outcomes. This report increases awareness of everolimus as a potentially causative agent for the development of angioedema.

Keywords

Angioedema lingual edema everolimus

Get full access to this article

View all access options for this article.

References

Fuchs

Zittermann

Berthold

. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79: 981–983.

Duerr

Glander

Diekmann

. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5: 703–708.

Mackenzie

Wood

. Lingual angioedema associated with everolimus. Acta Oncol 2010; 49: 107–109.

Chan

Soliman

. Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management. Ann Otol Rhinol Laryngol 2015; 124: 89–96.

Jeanmart

Malo

Carrier

. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002; 21: 990–998.

Rothenburger

Zuckermann

Bara

. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007; 26: 305–311.

Rothermundt

Gillessen

. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol 2013; 31: e57–e58.

Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 31 March, http://ctep.cancer.gov (2003, accessed 16 February 2016).

Baselga

Campone

Piccart

. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 2012; 366: 520–529.

10.

Dieval

Aelvoet

Van den Bulck

. Angioedema of the tongue in a patient with breast carcinoma treated with exemestane-everolimus in combination with an angiotensin-converting enzyme inhibitor. Belg J Med Oncol 2015; 9: 71–73.